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Abstract
Background: Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our 
institution with a carmustine (BCNU) - methotrexate (MTX) combination. We report here our clinical experience 
regarding this combination.
Patients and Methods: Patients were treated by a combination of BCNU 100 mg/m² on day 1 and MTX 600 mg/m² on 
day 1 and 15 of a 28 day cycle. Treatment was continued until progression or unacceptable toxicity.
Results: 50 patients were treated between 1999 and 2007. 94% of the patients presented with concomitant extra-
cerebral disease. Median number of previous metastatic setting chemotherapy regimens was 2 (0-5). Median number 
of cycles was 3 (1-20). There were 11 objective responses (23% [95%CI 12-37]) among 48 evaluable patients. Median 
progression-free survival and overall survival (OS) were 4.2 (95%CI: 2.8-5.3) and 6.9 (4.2-10.7) months respectively, with a 
one-year OS rate of 32% (20-46). Median Relative Dose Intensity for BCNU and MTX were 0.98 (0.31-1.1) and 0.96 (0.57-
1.66) respectively. There were 2 presumed treatment-related deaths. One patient developed febrile neutropenia. 
Performance status, BS-BM score and presence of liver metastases were associated with OS in univariate analysis.
Conclusions: This combination appears to be effective and well tolerated in good performance status BC patients 
presenting with BM.
Background
Fifteen to 30% of patients with advanced breast cancer
(BC) will develop brain metastases (BM) [1-6]. The vast
majority of BC patients with BM have a concomitant
extra-cerebral metastatic disease, pledging for systemic
treatments. Central nervous system (CNS) metastases
occur mainly within 2 years following a diagnosis of met-
astatic disease, with a 13 months median survival period
from the diagnosis of BM in the HER-2 positive tumors
setting [7]. Synchronous diagnosis of BC and BM is a rare
event, with a 28-34 months median interval between pri-
mary diagnosis and the development of CNS involvement
[5,8].
Prognosis of patients with multiple BM is poor, with a
median survival of <1 year. There is currently no
approved chemotherapy regimen for BM, and the current
standard of care involves whole-brain radiation therapy
(WBRT) and control of symptoms with steroids and anti-
convulsants [3]. However, WBRT can be associated with
a risk of neurotoxicity [9], and some patients refuse such
treatment. Furthermore, even if some selected patients
with recurrent metastases previously treated with WBRT
can be candidates for salvage stereotactic radiosurgery, a
majority of this population does not receive additional
brain irradiation. In addition, the existence of an extra-
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Various chemotherapy regimens have been investigated
in BC patients with BM. However, standard agents used
to treat BC, such as taxanes and anthracyclines, have
demonstrated conflicting results regarding their efficacy
in the treatment of BM [10,11]. The investigation of che-
motherapy efficacy for the treatment of BM has been lim-
ited because of a presumed lack of effectiveness due to
the blood-brain barrier (BBB). However, the importance
of the BBB is probably overrated in the case of the neoan-
giogenesis surrounding macroscopic metastases or
relapsed disease as the BBB has already been disrupted at
this stage, resulting from the newly developed blood ves-
sels not provided with the physiological properties of the
common BBB. In such a setting, chemotherapeutic agents
initially known not to cross the BBB, have been demon-
strated to penetrate metastatic tissue [12] and so could be
able to induce significant antitumor activity [11].
Methotrexate (MTX) is an active drug against breast
and other primary cancers and can be effective when
used at a high dose to reach the CNS and to achieve clini-
cal activity [13]. Carmustine (BCNU) has demonstrated
clinical activity in brain metastases from solid tumors
[14]. Considering the lack of standard treatment validated
in this population and the clinical activity of monother-
apy methotrexate and BCNU in BM patients, these
patients are treated in our Institution since 1999 with a
combination of BCNU and MTX. We report here our
clinical experience regarding the efficacy and safety pro-
file of this combination.
Patients and methods
Patient Eligibility
Patients treated in our institution and affected by BC BM,
diagnosed using either CT-scan or MRI of the brain, who
received the combination of BCNU and MTX were con-
sidered in this retrospective study. Patients were identi-
fied from the Breast Cancer database of the Val d'Aurelle
Medical Cancer Center, and records were reviewed for all
patients treated with at least one cycle of BCNU-MTX
for BC BM between 1999 and 2007. Identified patients
were then followed until death or until February 2008. To
be considered suitable for this treatment, patients had to
have an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) [15] between 0 and 3. Patients
were also required to have adequate bone marrow reserve
(neutrophils ≥ 1.5.109/L, platelets > 100.109/L). This
study was reviewed and approved by our Institutional
Review Board.
Treatment Plan
Patients were treated by the combination of BCNU and
MTX according to the proposal of our in-site Breast Can-
cer Multidisciplinary Committee. Treatment was contin-
ued until progression, unacceptable toxicity, inter-current
disease or patient's refusal to continue. The 4-week-based
chemotherapy regimen consisted of a combination of
BCNU 100 mg/m² and MTX 600 mg/m² on day 1 and
MTX 600 mg/m² on day 15. A cycle restarted at day 28
pending hematological recovery (absolute neutrophils
count ≥1.5.109/L and platelets > 100.109/L) and return to
grade 0 or 1 for non hematological toxicity. If one or more
of these conditions was not met, then a 1- to 2-week delay
was allowed for recovery. A 50% dose reduction was
applied to BCNU in case of severe toxicity (grade 4 neu-
tropenia ≥ 7 days during the previous cycle; grade 3 or 4
febrile neutropenia; grade 3 or 4 infection with neutrope-
nia; grade 4 anemia or thrombocytopenia or bleeding
requiring transfusion, or any grade ≥ 3 non-hematologi-
cal toxicity). The drug was discontinued in case of a sec-
ond occurrence of severe toxicity. Methotrexate was
administered on day 15 depending on hematological
recovery and return to grade 0 or 1 for non-hematologi-
cal toxicity. Urinary alkalization using sodium bicarbon-
ate (in order to obtain a urinary pH > 7.5) was based on a
4 h 500 ml infusion of 4.2% sodium bicarbonate before
MTX infusion, followed by a 12 h 1.5 l infusion of 1.4%
sodium bicarbonate solution. Folinic acid supplementa-
tion (25 mg every 6 hours day 2 to 5 and day 16 to 19) was
systematically used to minimize methotrexate hemato-
logical toxicity. Patients presenting with HER-2 over
expressing tumors received in addition (when commer-
cially available) trastuzumab injections at the dose of 4
mg/kg on days 1 and 15 of the same cycle. Granulocyte
colony-stimulating factors were used as secondary neu-
tropenia prophylaxis in case of delays in chemotherapy
due to long lasting neutropenia. Concerning patients
receiving endocrine treatment, the treatment was discon-
tinued at the initiation of the chemotherapy combination.
Study Assessments
Pretreatment evaluation included a complete medical
history and clinical examination with tumor measure-
ments (imaging studies and physical examination when
appropriate), appropriate radiological tests, concomitant
treatments, PS, and hematological and biochemical pro-
files. Tumor measurements were performed every other
cycle during the treatment course and every 3 months
subsequently until progression. During the treatment
duration, complete blood counts including a platelet and
leukocyte differential count were performed weekly.
Response and Toxicity Criteria
CT-scans of the brain, chest, abdomen and pelvis were
performed before the initiation of chemotherapy, then
every 8 weeks (2 cycles) until disease progression or che-
motherapy stop. For this retrospective analysis, patients
were evaluated for response and progression according to
the RECIST criteria [16]. A minimal duration of 4 weeks
was required to document a response, and the best
response was recorded for each patient. A patient withJacot et al. BMC Cancer 2010, 10:257
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cerebral and extra-cerebral disease was considered as a
responder if there was a significant (as per RECIST crite-
rion) decrease of both cerebral and extra-cerebral lesions.
Progressive disease was defined as cerebral and/or extra-
cerebral progression of the disease. We considered clini-
cal benefit as a disease stabilization lasting at least 6
months or an objective response. Progression-free sur-
vival was defined as the time from the date of BCNU-
MTX treatment initiation until the date of progression or
death. Survival was defined as the time from the date of
treatment initiation to the date of death. Toxicity, graded
according to the National Cancer Institute Common Tox-
icity Criteria (NCI-CTC, version 3.0), was assessed by
clinical examination and biological tests before each cycle
of chemotherapy.
Statistical Considerations
Estimates of median progression-free survival, and over-
all survival with their 95% confidence intervals (CI) were
calculated using the Kaplan-Meier product-limit method
[17]. For toxicity analyses, the worst grade for each cycle
of chemotherapy was used. Treatment compliance was
evaluated for each drug by the Relative Dose Intensity
(RDI), defined as the ratio of actual dose intensity for
e a c h  d r u g  ( t o t a l  a d m i n i s t e r e d  d o s e  p e r  u n i t  o f  t i m e ,
expressed in mg/m²/week) to the planned dose per unit
of time [18]. The relative dose intensity of BCNU and
methotrexate by patient was calculated as the average
RDI for all drugs. In addition, we performed an explana-
tory analysis to identify the prognostic factors affecting
this population. Patients without clinical events at the
date of February 29th, 2008 were censored at this date,
excepted in cases of patients previously lost to follow-up.
The statistical analyses were performed using STATA
v9.0.
Results
Patients
From 1999 to 2007, 50 patients were treated with this
combination. Patients' characteristics at the time of BM
diagnosis are summarized in Table 1. Median age at the
time of BM diagnosis was 54 years. Median time between
diagnosis of BC and BM was 37 months (0-180). Only 1
patient presented with synchronous BM. Roughly two-
thirds of the patient population was ECOG PS 0 or 1. No
tumor was recorded to be Scarf, Bloom and Richardson
(SBR) grade I, 40% were hormonal receptor negative and
50% of the 36 tumors analyzed for HER-2 amplification
were positive. Ninety four percent of the patients pre-
sented with concomitant extra-cerebral disease, mainly
bone (76%), liver (46%), lung (42%) and lymph node (26%)
metastases. The median number of previous chemother-
apy regimens in the metastatic setting was 2 (0-5).
Twenty four patients (92% of the HR positive population)
received previous hormonal therapy, either in the adju-
vant or metastatic setting. The BM-associated clinico-
radiological characteristics are summarized in Table 2.
Six patients were clinically asymptomatic at the time of
BM diagnosis. Only 5 patients presented with seizures
and were treated with various anticonvulsants, preclud-
ing the analysis of an eventual interaction between con-
comitant medications and the chemotherapy efficacy and
toxicity. No patients received prophylactic anticonvul-
sants. Thirty nine patients (78%) were treated by WBRT
before the initiation of the BCNU-MTX chemotherapy
(median dose 30 Gy, range 18 to 40). Due to the presence
of cerebral and extra-cerebral disease, in order to treat
extra-cerebral disease, the chemotherapeutic treatment
was started shortly after the completion of the WBRT.
Thirty three patients received planned chemotherapy
immediately (less than one month after radiation therapy
completion), and six patients received the combination
chemotherapy as a salvage treatment after WBRT failure.
Three patients (6%) had surgery and 2 patients were
treated by radiosurgery (4%). Six patients were treated by
the chemotherapeutic combination without previous
radiotherapeutic or surgical treatment. Median time
from BM diagnosis to initiation of chemotherapy was 1.3
months (range 0.1 to 8 months). Only 4 patients initiated
chemotherapy more than 4 months (8 months) after the
BM diagnosis.
Treatment Exposure
A total of 256 chemotherapy cycles were administered to
50 patients, with a median number of 3 (1-20) cycles and
a 12.9 week median treatment duration (range 2-91).
Thirty percent of the patients received up to 6 chemo-
therapy cycles, with 20% patients continuing the treat-
ment after 6 cycles. Thirty four percent of the patients
discontinued their treatment before the third cycle. The
characterization of this population is explored on the
prognostic factors section. Concerning the HER-2 over-
expressed population, 8 patients received 48 cycles of the
combination BCNU-MTX and trastuzumab.
Chemotherapy dose modifications and delays of BCNU
and MTX are summarized in table 3. The median RDI for
BCNU and MTX were 0.98 (0.31-1.1) and 0.96 (0.57-
1.66) respectively. Two patients received a MTX dose of 1
g/m², thus explaining the upper MTX RDI limit of 1.66.
Efficacy
There were 11 objective responses (23% [95%CI 12-37])
among 48 evaluable patients, with an additional 10%
patients achieving disease stabilization lasting at least 6
months (5 patients), for a total clinical benefit rate of 33%.
Two patients died of disease progression on the first 2
treatment weeks and were considered as non responders.
Two patients were completely resected before the chemo-
therapy initiation and thus are not evaluable for response.
Median response duration was 6.5 months (0.8 - 19.5).Jacot et al. BMC Cancer 2010, 10:257
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Table 1: Patient characteristics at the time of BM diagnosis
Patient characteristics Nb patients %
Age at BM diagnosis (years)
Median, range 54 (28-79)
Time between initial diagnosis 
and BM diagnosis (months)
Median, range 36.8 (0-180)
Histology
Lobular 6 12
Ductal 43 86
Other 1 2
SBR grade
I0 0
II 23 46.9
III 26 53.1
Not known 1
Inflammatory breast cancer
Yes 11 22.9
No 37 77.1
Not known 2
Hormone receptor status
ER-/PR- 19 40
ER-/PR+ 1 4
ER+/PR- 18 40
ER+/PR+ 7 16
Not known 5
HER-2 status
0 14 38.9
1+ 25 . 6
2+ 38 . 3
3+ 17 47.2
Not known 14
Number of previous 
chemotherapy lines
Median, range 2 (0-5)
ECOG Performance status
01 9 3 8
11 3 2 6
21 4 2 8
34 8
Weight loss (%)
Median, range 0 (0-15)
RPA score
12 4
24 4 8 8
34 8Jacot et al. BMC Cancer 2010, 10:257
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Median disease stabilization duration was 11.4 months
(8.6 - 22.2+). Considering the HER-2 positive population
treated by the BCNU-MTX trastuzumab combination (8
patients), 3 patients achieved a partial response and 2
additional patients achieved SD lasting more than 6
months. At the time of the current statistical analysis, 44
patients had a disease progression and 43 patients died.
Thirty nine patients died from disease progression. In
addition, there were 2 presumed treatment-related deaths
(one case of acute renal failure at D6 of the first chemo-
therapy cycle, one patient developed a lethal febrile neu-
tropenia 30 days after the fourth chemotherapeutic
cycle). One patient was lost to follow-up, one patient died
of an unrelated cause (myocardial infarction). Seven
patients are still alive, 2 of them without evidence of
residual disease. Median PFS was 4.2 months (95%CI:
2.8-5.3), with a one year PFS rate of 20.5% (10.3-33.2)(Fig.
1). First progression site was cerebral in 44% of the cases,
BS-BM score
01 2
12 1 4 2
22 6 5 2
32 4
Local relapse
Yes 11 22.4
No 38 77.6
Extra cerebral metastases
Yes 47 94
No 3 6
Extra cerebral metastases 
(sites)
Bone 38 76
Liver 23 46
Lung 21 42
Lymph nodes 13 26
Others 9 18
Abbreviations used: BM: Brain metastases; RPA Score: Recursive partitioning analysis score; SBR Grade: Scarf Bloom and Richardson Grade; 
ER: Estrogen Receptor; PR: Progesterone Receptor; BS-BM: Basic Score for Brain Metastases.
Table 1: Patient characteristics at the time of BM diagnosis (Continued)
Table 2: Brain metastases-associated characteristics
Brain Metastases 
characteristics
Number of patients %
Number of brain metastases
Median, range 4 (1-21)
Brain metastases localization
Supratentorial 13 26
Infratentorial 5 10
Supra and infratentorial 32 64
Associated symptoms
Headaches, Nausea and 
Vomiting
38 76
Neurological deficiency 19 38
Seizures 5 10
Change in mental status 3 6Jacot et al. BMC Cancer 2010, 10:257
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outside the brain in 36%, and both intra- and extra-cere-
bral in 19% of the cases. Median overall survival of the
whole population is 6.9 months (4.2-10.7), with a one-
year OS rate of 32% (20-46) (Fig. 2). These survival data
were 7.7 (0.4-NR) and 14.1 (0.4-NR) months respectively
for PFS and OS in the population of 8 patients treated
with trastuzumab and 3.5 (2.5-4.7) and 5.9 (3.9-8.2)
months respectively for PFS and OS in the 42 patients
population without trastuzumab treatment.
Safety
Worst NCI-CTC toxicity grades experienced by patients
during the chemotherapy cycles are given in Table 4.
Myelosuppression was the most common toxicity. Neu-
tropenia was observed in 56% of cycles; however grade 3-
4 neutropenia was observed in only 16% of the cycles.
One case of febrile neutropenia was recorded, leading
one month later to the patient's death. However, the clini-
cal presentation was unusual, with a long lasting neutro-
penia without complete recovery one month later. Grade
2-4 anemia was a rare event (16.5% of cycles). Severe
(grade 3-4) thrombocytopenia was observed in only 4.8%
of the cycles. No hemorrhagic episode was reported and
no patient required platelets transfusion. Besides myelo-
suppression, adverse events (AEs) possibly or probably
related to study drugs were usually mild in severity and
manageable. The most common grade 2-4 extra-hemato-
logical AE was fatigue. Emesis was an uncommon event,
with nearly 80% of the cycles with grade 0 emesis. Con-
sidering alopecia, the determination of this toxicity fre-
quency and grade is difficult considering the high
proportion of patients previously treated by whole brain
radiation therapy. None of the patients treated by this
chemotherapeutic combination without previous radia-
tion therapy to the brain suffered from alopecia. There
were no reports of chemotherapy-induced neurological
side effects.
After treatment failure, 48% (24 patients) of the
p a t i e n t s  r e c e i v e d  a d d i t i o n a l  c h e m o t h e r a p e u t i c  o r  h o r -
monal treatments (1 regimen for 11 patients, 2 regimens
for 6 patients, 3 regimens for 3 patients, 4 regimens for 4
patients and 7 regimens for 1 patient) and one patient was
lost to follow-up.
Prognostic factors
Considering the relatively modest number of patients
analyzed in this study, the exploratory analyses of prog-
nostic factors affecting this population must be consid-
ered with caution.
Table 3: Chemotherapy dose modifications and delays
Cycles (n = 256) Patients (n = 50)
Methotrexate dose 
modification
35 13.7% 14 28%
BCNU dose 
modification
38 14.8% 14 28%
Any dose modification 55 21.5% 18 36%
Cycle delay 22 8.6% 10 20%
Figure 1 Progression Free Survival Figure 2 Overall SurvivalJacot et al. BMC Cancer 2010, 10:257
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In univariate analysis, PS 0-1 versus 2-3, BS-BM (Basic
Score for Brain Metastases) score 0-1 versus 2-3 and
presence of liver metastases were the only factors signifi-
c a n t l y  a s s o c i a t e d  w i t h  p r o g n o s i s .  P S  a p p e a r s  t o  b e  a
strong prognostic factor, with a significantly higher 1-
year survival rate (47.8% [30% - 60%] versus 5.5% [0% -
20%], p = 0.0002) and a longer median overall survival
time (11.9 months [6.9 - 20.4] versus 2.9 months [0,7 -
4.7]) in the population of patients with PS 0 or 1 as com-
pared to 2-3 (Fig. 3). Similarly, patients with a BS-BM
score 2 or 3 had a significantly better prognosis than
those with scores 0 or 1 (1-year survival 47% versus 14%,
median overall survival 10.7 months [6.9 - 23.8] versus
3.9 months [0.75 - 5.49], respectively, p  = 0.0007).
Patients affected by liver metastases had a significantly
worse prognosis than those without liver metastases (1-
year survival 19.6% [6.3 - 38.2] versus 43% [24 - 60.7],
median overall survival 3.9 months [1.1 - 8.2] versus 10.7
months [5.5 - 23.8], respectively, p = 0.0007). Neither hor-
mone receptor status (negative versus one or both posi-
tive receptors) nor HER-2 status were found to be
significantly associated with progression-free survival or
overall survival (HER-2 status 0-1+ versus 2-3+: 1-year
survival 28% versus 49%, median overall survival 6.4
months [2.9 - 31.6] versus 8.4 months [2.1 - 22.5], respec-
tively, p = 0.77; 1-year progression-free survival 32% ver-
sus 15%, median progression-free survival 3.0 months
[2.4 - 18.9] versus 5.1 months [2.2 - 8.1], respectively, p =
0.78). No statistical difference was observed for overall
survival or progression-free survival between patients
previously treated with 0-2 chemotherapeutic lines ver-
sus patients with 3+ previous chemotherapeutic lines.
However, due to the small sample size of this study, sig-
nificant and non significant results of the effects in par-
ticular subgroups needs to be interpretaed with extreme
care. Considering this, a multivariate analysis was not
performed.
At the same time, we tried to characterize the popula-
tion of patients who were not able to complete the first 2
chemotherapy cycles due to toxicity, disease progression
or performance status alteration. This population of 17
patients was affected with a really poor prognosis, with a
median overall survival of one month [0.5 - 2.9]. Two-
thirds of this population had a PS 2 or 3 and had BS-BM
Figure 3 Overall Survival according to Performance Status
Table 4: Maximal toxicity (by chemotherapeutic cycle)
Grade
01234
Anemia 98
(39.4%)
110
(44.2%)
36
(14.5%)
4
(1.6%)
1
(0.4%)
Neutropenia 109
(43.8%)
53
(21.3%)
47
(18.9%)
31
(12.4%)
9
(3.6%)
Leucopenia 107
(43.0%)
44
(17.7%)
62
(24.9%)
33
(13.3%)
3
(1.2%)
Thrombocytopenia 155
(62.2%)
69
(27.7%)
13
(5.2%)
6
(2.4%)
6
(2.4%)
Fever 241
(99.6%)
01
(0.4%)
00
Emesis 187
(78.9%)
45
(19%)
5
(2.1%)
00
Fatigue 32
(13.4%)
169
(70.7%)
33
(13.8%)
5
(2.1%)
0
Alopecia 64
(33.0%)
22
(11.3%)
44
(22.7%)
64
(33%)
-Jacot et al. BMC Cancer 2010, 10:257
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scores of 0 or 1. Also, liver metastases were present in
70% of the patients, a far more elevated percentage than
in the whole study population.
Discussion
BM of BC remains a clinical situation associated with
poor prognosis, affecting mainly patients with metastatic
disease outside the brain, and previously treated by sev-
eral chemotherapeutic agents. In our study, patients pre-
viously received a median of 2 chemotherapy regimens
before BM diagnossis. In addition, this clinical situation is
a classical exclusion criterion of most clinical trials, pre-
cluding clinical data regarding the efficacy and toxicity of
chemotherapeutic agents in this setting. However, the
overall survival of our population is coherent with the
ones reported by other clinical studies of third line che-
motherapeutic agents in patients affected by metastatic
BC without BM [13,19-22]. Prognosis after radiation
therapy remain poor, with a median survival of 3 to 6
months and a 1-year survival of 15% [23,24]. This poor
prognosis can be at least partially explained by the coexis-
tence of an active extra-cerebral disease, remaining the
main cause of death in this population [25]. These data,
associated with the disruption of the BBB by the neoan-
giogenic switch associated with BM, supports the use of
systemic treatment in patients affected with BM [11], in
order to delay BM progression, to treat the concomitant
extra-cerebral disease and to improve survival. A growing
number of publications is supporting this idea, and the
use of chemotherapy has even been identified as a prog-
nostic factor in this population [24]. From a theoretical
point of view, the BCNU-MTX combination, using non
cross-resistant drugs not usually used in first or second
line treatment of metastatic BC, was a good candidate for
such a clinical setting.
Our population was affected with classical negative
prognostic factors of metastatic BC, and of BM (young
age, high SBR grade, high frequency of hormonal recep-
tor-negative tumors, active extra-cerebral disease in 94%
of the cases, altered PS) [11,26,27]. Only 2 patients can be
classified in a good prognostic group considering RPA
(Recursive partitioning analysis) or BS-BM classification.
It is interesting to note that these 2 patients, as well as the
2 patients alive without evidence of intracranial disease,
were in the radiation therapy group and that their BM
were not surgically resected. However, considering such a
poor prognostic group, in an unselected population, the
results of this retrospective study are encouraging, with a
clinical benefit rate of 33%, an overall response rate of
23% and a median overall survival of 6.9 months. These
results compare favorably with other reported third line
chemotherapeutic regimens in more selected patients not
affected by BM [13,19-22]. In addition, it is important to
note, while comparing to whole brain radiation therapy
alone, that our survival data are calculated from the start
of the chemotherapy cycles and that 89% of the patient
population received previous radiation therapy, with a
median time from BM diagnosis to initiation of chemo-
therapy of 1.3 months. Thus, the overall survival of our
population from the time of diagnosis of BM must be
considered longer, roughly equal to 9.1 months (5.2-13.2)
in our study. All these data compares favorably with pre-
vious regimens reported in this setting of BM from BC
(Table 5). Another important issue is the risk of over-
evaluation of the clinical efficacy of a chemotherapeutic
regimen initiated a few weeks after the end of the WBRT.
However, 94% of the patients' population presented with
extra-cerebral disease, and, to be classified as responder, a
patient needed to have a significant response at the cere-
bral and extra-cerebral sites avoiding such a confounding
effect of WBRT.
Considering the safety profile of this regimen, we were
able to achieve a RDI greater than 90% for each of the 2
drugs. Dose reductions were applied in one third of the
patients but there was no treatment discontinuation due
to unacceptable toxicity. Clinically relevant toxicity is
rare, and grade 3-4 hematological toxicity was rarely
complicated. Only one patient presented a febrile neutro-
penia after 5 chemotherapy cycles, and died one month
later due to a septic shock. The toxicity profile of the
BCNU-MTX regimen appears rougly comparable with
the aforementioned studies of chemotherapy in this set-
ting [13,22,26,28,29]. In our opinion, this association can
be considered as an option in BM BC patients previously
pretreated by anthracyclins, taxanes and capecitabine.
H o w e v e r ,  i n  s u c h  a  p o o r  p r o g n o s t i c  s i t u a t i o n ,  i t  i s
important to identify factors associated with prognosis
and with early treatment failure in order to avoid a useless
and potentially toxic treatment and to target the popula-
tion more likely to benefit from this regimen. One way to
achieve this goal is to identify prognostic factors in this
study. Use of prognostic index in patients suffering from
brain metastases is an important issue in studies assess-
ing the prognosis of this population. Our population of
patients was analysed using two different stratification
scores (RPA scoring system and BS-BM). RPA has been
demonstrated as the most efficient scoring system in
large populations [30]. However, when analysing our pop-
ulation of patients, there is a striking imbalance when
using the RPA score (4%, 88% and 8% respectively of the
patients were affected by RPA score I, II and III), preclud-
ing a reliable statistical analysis. Prognostic classification
using the BS-BM scoring system allowed a more balanced
distribution of the patients in two groups and was thus
considered in our statistical analysis. PS was identified as
a strong prognostic factor, together with BS-BM score.
However, it is important to consider that PS is a part of
the items used to calculate the BS-BM score, leading to aJacot et al. BMC Cancer 2010, 10:257
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large redundancy between theses 2 univariate prognostic
factors. A chemotherapeutic treatment does not seem
i n d i ca t ed  i n  B M  BC  pa t i e n ts  wi t h  a n  a l t e r ed  PS,  ev e n
more so if the patient is presenting with liver metastases.
This poor prognosis population may be considered for
best supportive care.
Another critical issue in this population is the influence
of her-2 overexpression status on survival or disease free
survival. In our study population, 55.5% of the patients
with known HER-2 expression presented with HER-2 2+
or 3+ tumours, however Her-2 status had no statistical
impact on survival or disease free survival. These results
are conflicting considering other clinical studies in this
setting. Eichler et al.[31] evaluated 83 BC patients with
BM and concluded that HER-2 status was a strong pre-
dictor of survival in this population, with a reported pro-
longed survival of the HER62-positive population after
the diagnosis of BM compared with HER-2-negative
patients (17.1 months vs 5.2 months; P 5 .001). Nam et
al.[32] have found in a population of 126 patients that
metastatic BC who developed BM had higher propor-
tions of triple-negative and HER2+/ER- tumour status.
These data are in accordance with our results. In addi-
tion, they reported that HER-2 positive patients were
affected with a more favourable clinical outcome than
HER-2 negative patients, and more specifically that a sig-
nificant survival benefit was noted in HER2-positive BM
patients treated with trastuzumab when all 126 patients
were compared in the following three groups: 21 HER2-
positive patients who received trastuzumab after the
onset of BM (12.8 months) vs 35 HER2-positive patients
who did not receive trastuzumab after the onset of BM
(4.0 months) vs 70 HER2-negative patients (3.4 months)
(p = 0.0011). It is thus possible that the prognostic signifi-
cance of the HER-2 status is linked to the therapeutic effi-
cacy of trastuzumab-based treatments in this population.
The differences between these 2 studies and our results
can be related to the small sample size of our patient's
population and to the limited use of trastuzumab in the
HER-2-positive population (8 patients). These data, alto-
gether with the expanded results of the Nam study
reported by Park et al.[33] support the use of anti-HER-2
targeted therapies in BC patients with BM, even if they
were previously treated with trastuzumab-based regimen.
Conclusion
Despite the limitation of being a retrospective study, in
this population of heavily pretreated patients affected by
BC BM, the BCNU-MTX combination appears to be an
effective and well tolerated combination. In the absence
of standard chemotherapeutic treatment of BC BM, this
combination appears to be a reasonable option in patients
with good performance status.
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Table 5: Chemotherapeutic trials in breast cancer patients metastatic to the brain
Chemotherapy N Clinical study 
type
Objective 
response rate 
(%)
Progression-free 
survival 
(months)
Overall survival 
(months)
Reference
Cyclophosphamide, 
5FU, methotrexate*
22 Prospective 59 (37-80) NR 6.3 (0.5-20.8) Boogerd et coll. 
(1992)[26]
Cisplatine etoposide 56 Prospective 38 (NR) 4,3 (0-71,8) 7.8 (0-71.8) Franciosi et coll. 
(1999)[28]
Temozolomide 
capecitabine
24 Phase I 18 (NR) 3 (0.8-17.5) NR Rivera et coll. 
(2006)[29]
HD Methotrexate 32 (29 BC) Retrospective 28 (NR) NR 4.6 (0.7-31.2) Lassman et coll. 
(2006)[13]
Capecitabine 7 Retrospective 28 (NR) NR NR Ekenel et coll. 
(2007)[22]
Lapatinib** 39 Phase II 2,6 (0,2-26) 3 (2.3-3.7) NR Lin et coll. 
(2008)[34]
Lapatinib** 242 Phase II 6 (3.6-10.2) 2.4 (1.87-2.79) 6.37 (5.49-8.25) Lin et col. 
(2009)[35]
Carmustin 
methotrexate (present 
study)
50 Retrospective 23 (12 - 37.3) 4.2 (2.8-5.3) 6.9 (4.2-10.7)
* 2 patients received doxorubicin instead of methotrexate
** HER-2 overexpressed tumors
NR: Not reportedJacot et al. BMC Cancer 2010, 10:257
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